Green Cross, MacroGenics initiates Phase I study of MGAH22

Green Cross said Friday that the company and US-based MacroGenics have jointly conducted a multinational Phase I clinical trial of MGAH22, an Fc-optimized monoclonal antibody developed by MacroGenics which has been shown, in pre-clinical studies, to reduce tumor growth significantly in a broad panel of HER2-expressing tumors.

MGAH22, an Fc-modified monoclonal antibody, targets the HER2 oncop...